Interview with Carlos Kiffer, President, GC-2
As I was doing research on your company, GC-2, I was unable to find a lot of information since it is a rather new company. Could you bring me up…
Address: Av. Nações Unidas, 12.399, 12º andar, cj 125 A, Edifício Landmark CEP 04578-000, São Paulo – SP,Brazil
Tel: (11) 3528 7406
Web: http://www.gcdois.com.br/
GC-2, in tune with the surge in R&D for pharmaceutical products in the region, provides intelligent solutions for this interdisciplinary scenario.
The natural growth of pharmaceuticals in the region, including herbal medicines and biotechnology products, has caused a parallel demand for project management. However, GC-2 is not just one more consulting firm. We bring the Project Management Office concept to pharmaceutical R&D.
In order to strengthen the strategic decision making process in pharmaceutical drug and product development, GC-2 offers its clients alternatives for the technical and commercial scientific monitoring of their developments:
Technical and scientific viability and patentability, Conceptualization & positioning, Structuring & management, Production and quality insurance interface, Pre-clinical pharmacological development interface, Pre-clinical toxicological development interface, Clinical development, Public agency interface, Antimicrobial development
As I was doing research on your company, GC-2, I was unable to find a lot of information since it is a rather new company. Could you bring me up…
The Brazilian pharma market outperformed the Latin American average in Q1 of 2020 with a growth of 8.2 percent in real terms (inflation adjusted), according to IQVIA. Its size reached…
Six of the top ten companies in the Brazilian pharma market are domestic.* Read on for an introduction to some of the Brazilian giants that are perhaps less well known…
Panorama Faramceutico’s editorial team look at how the ongoing COVID-19 pandemic stands to affect Brazil’s over the counter (OTC) market segment during and after the COVID-19 pandemic.* The OTC…
In the race to develop the world’s first COVID-19 vaccine, Brazil – now one of the world’s worst-affected countries – is becoming an attractive clinical trial destination for biopharma companies…
The editorial team at Panorama Farmaceutico explain how the COVID-19 pandemic and global trade flow stoppages are impacting the manufacture and supply of medicines within Brazil.* The COVID-19 pandemic…
The editorial team at Panorama Farmaceutico explain why coordinated action is needed within Brazilian pharma to reduce dependence on API imports from abroad and increase medical sovereignty. * The…
Below we highlight recent news in Brazilian pharma, including the impact of coronavirus as well as legal and regulatory updates. Proposal to allow breaking of patents due to Covid-19…
Swiss pharma giant Novartis is teaming up with the Oswaldo Cruz Foundation (Fiocruz) in Brazil to conduct research throughout Latin America on neglected diseases. This agreement establishes an exchange…
Three seasoned pharma executives with a wealth of experience working in Brazil offer their insights on leadership strategies for success in the massive, but complex, Brazilian pharma market. …
Rodrigo Araujo of global organizational consulting firm Korn Ferry outlines what he sees as the leadership profile of the future – agile, digital, self-aware, and able to transform both themselves…
When combining the sheer size of Brazil – the fifth largest country in the world – with its tropical climate, its largely perfectible infrastructure, and the soaring importance of temperature…
“Brazil undoubtedly holds great development opportunities for the global pharmaceutical and healthcare industries,” boldly states Minister of Health Ricardo Barros, “and we hope to gain the trust of an increasing…
See our Cookie Privacy Policy Here
